title: 99Tcm-HMPAO and 99Tcm-DTPA radioaerosol clearance measurements in idiopathic pulmonary fibrosis.
abstract: The clearance rate of an inhaled aerosol of a lipophilic complex, 99Tcm-hexamethylpropyleneamine oxime (99Tcm-HMPAO), was compared with that of a hydrophilic complex, 99Tcm-diethylenetriamine pentaacetate (99Tcm-DTPA), in nine normal subjects and in eight patients with idiopathic pulmonary fibrosis (IPF). Data were acquired as follows. The subjects were placed supine with their back against the scintillation camera and breathed aerosol for 2 min; pulmonary radioactivity was then monitored for 30 min. A time-activity curve (TAC) was generated from the region of interest (ROI) over the periphery of each lung field and a computer program was then used to calculate percentage clearance per minute (k) in each lung. The mean (+/- S.E.M.) rate of clearance of 99Tcm-DTPA (k = 1.31 +/- 0.13% min-1) was not significantly different from that of 99Tcm-HMPAO (k = 1.32 +/- 0.27% min-1, P > 0.025) in the normal subjects. However, 99Tcm-DTPA clearance was 1.91 +/- 0.27% min-1 and 99Tcm-HMPAO clearance 0.78 +/- 0.17% min-1 in eight patients with IPF (P < 0.001, 99Tcm-DTPA vs 99Tcm-HMPAO). By regression analysis using a multiplicative model, both values correlated fairly [r = -0.71, y = exp (0.08-0.85 ln chi); P < 0.005], with a change in clearance rate in the opposite direction in all eight patients. The results of our study demonstrate that the pulmonary clearance of 99Tcm-HMPAO is different from that of 99Tcm-DTPA in IPF.
authors.affiliation: Department of Nuclear Medicine, Chest Department, Taipei Veterans General Hospital, Taiwan.
authors.forename: S H
authors.initials: SH
authors.lastname: Yeh
authors.forename: R S
authors.initials: RS
authors.lastname: Liu
authors.forename: L C
authors.initials: LC
authors.lastname: Wu
authors.forename: N J
authors.initials: NJ
authors.lastname: Peng
authors.forename: J Y
authors.initials: JY
authors.lastname: Lu
mesh_terms: D000336:Aerosols; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015609:Organotechnetium Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics; D010091:Oximes / Q000008:administration & dosage / Q000493:pharmacokinetics; D010539:Permeability; D011658:Pulmonary Fibrosis / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000503:physiopathology; D012016:Reference Values; D012129:Respiratory Function Tests; D012984:Software; D019690:Technetium Tc 99m Exametazime; D016284:Technetium Tc 99m Pentetate / Q000008:administration & dosage / Q000493:pharmacokinetics; D014055:Tomography, Emission-Computed
chemical_list: D000336:Aerosols; D015609:Organotechnetium Compounds; D010091:Oximes; D019690:Technetium Tc 99m Exametazime; D016284:Technetium Tc 99m Pentetate